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Targeting T Cell Metabolism in
Inflammatory Skin Disease
Leonhard von Meyenn, Nicole Leonie Bertschi and Christoph Schlapbach*
Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
A properly functioning T cell compartment is crucial to protect the host from infections,
tumors, and environmental substances. In recent years, it has become increasingly clear
that the processes underlying proper T cell activation, proliferation, and differentiation
require well-tuned and dynamic changes in T cell metabolism. Thus, proper metabolic
reprogramming in T cells is crucial to ensure proper immunity in the context of infection
and anti-tumor immunity. Conversely, aberrant regulation of T cell metabolism can impair
T cell function and thereby contribute to T cell-mediated disease. In this review, the
relevance of recent insights into T cell metabolism for prototypical T cell-mediated skin
diseases will be discussed and their therapeutic potential will be outlined. First, the
major modules of T cell metabolism are summarized. Then, the importance of T cell
metabolism for T cell-mediated skin diseases such as psoriasis and allergic contact
dermatitis is discussed, based on the current state of our understanding thereof. Finally,
novel therapeutic opportunities for inflammatory skin disease that might emerge from
investigations in T cell metabolism are outlined.
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INTRODUCTION
T cells are key players of the adaptive immune system by acting as potent effectors and regulators of
immunity. Adaptive T cell immunity results from clonal expansion of antigen-specific T cells that
were activated by their cognate antigen presented by dendritic cells in secondary lymphoid organs
(1). After priming of naive T cells, multiple subsets of effector and memory T cells with different
phenotypic and functional properties are generated. Effector T cells (TEFF) migrate to peripheral
tissues and inflamed sites to fight infection. After successful clearance of the invading antigen,
the vast majority of effector cells die, leaving behind a small population of long-lived memory T
cells (2). In case of re-exposure to previously encountered pathogens or antigens, memory T cells
provide rapid and effective protective immunity.
Based on their migratory properties, memory T cells can be categorized in three major subsets:
Central memory T (TCM) cells, effector memory T (TEM) cells, and the recently identified tissue-
resident (TRM) cells. TCM cells express the chemokine receptor CCR7 and the vascular addressin L
selectin (CD62L), enabling them to circulate between lymph nodes and blood. TEM cells express
tissue-homing receptors that grant them access to peripheral tissues. Skin-homing TEM, for
instance, express the E-selectin ligand Cutaneous Lymphocyte Antigen (CLA), which allows them
to enter the skin, whereas the integrin α4β7 permits gut-homing TEM to enter the gut (3). TRM cells
are non-recirculating memory T cells that persist long-term in epithelial barrier tissues and provide
rapid front-line immune protection in peripheral tissues (4).
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It is now increasingly understood that T cell identity and
function are intertwined with metabolic pathways that are
required for energy and substrate generation on the one hand, but
also act to regulate effector functions, differentiation, and gene
expression on the other hand (5). In this review, we will first
summarize the current literature on T cell immunometabolism.
Then, we will explore how the cutaneous environment in
inflammatory skin disease might shape and influence T cell
function via the modulation of T cell metabolism and look ahead
on therapeutic opportunities that might arise therefrom.
MODULES OF T CELL METABOLISM
Glycolysis
After activation by cognate antigen, T cells rapidly increase their
glucose uptake by upregulating the cell surface expression of
glucose transporters such as GLUT1 (6). Once in the cytosol,
glucose immediately enters the glycolysis pathway in which
glucose is metabolized to pyruvate by a series of enzymatic
reactions (Figure 1). At the same time, lactate excretion increases
as a consequence of enhanced conversion of pyruvate to
lactate, indicating that T cells engage in aerobic glycolysis
(Figures 1, 2). Aerobic glycolysis describes the reduction of
pyruvate to lactate in the presence of oxygen, instead of its
oxidative phosphorylation (OXPHOS) in the mitochondria via
the tricarboxylic acid (TCA) cycle. This process of aerobic
glycolysis is also referred to as the “Warburg effect” in cancer
cells (7).While aerobic glycolysis generates less ATP permolecule
of glucose than OXPHOS, aerobic glycolysis yields metabolic
intermediates important for cell growth and proliferation, and
contributes to the cellular redox balance (NAD+/NADH) (8).
During the 10 enzymatic steps of glycolysis in which glucose is
converted to pyruvate, a variety of intermediates are generated
that are used in different biosynthetic pathways. These include
the pentose phosphate pathway, serine biosynthesis, de novo
fatty acid synthesis, and hexosamine biosynthesis. The pentose
phosphate pathway, for instance, donates important precursors
for nucleotide synthesis and is thus of crucial importance for
cell growth (9–11). As a consequence, glycolysis is not only an
energy-generating pathway for T cells, but also a metabolic basis
for anabolic biosynthesis and proliferation (10).
The rapid changes in T cell metabolism after activation
are regulated by a number of transcription factors and
signaling pathways (8). Signals from cytokines such as IL-2
lead to upregulation of nutrient transporters. Ligation of the
co-stimulatory molecule CD28 induces phosphatidylinositol-
3-kinase (PI3K)-dependent phosphorylation of Akt (12, 13).
Phosphorylated Akt induces expression and translocation of
glucose transporters to the cell surface, enhances activity of
glycolytic enzymes and activates key metabolic regulators such
as mTOR (14). mTOR is a central orchestrator of T cell
metabolism and is crucial for upregulation of glycolysis in
activated T cells (15) (Figure 2). Further transcription factors
involved in regulating activation-induced glycolysis are c-Myc,
estrogen receptor α (ERRα) and hypoxia inducible factor-1α
(HIF-1α) which coordinately drive the expression of genes
involved in metabolism to fuel the bioenergetic needs of clonal
expansion (8, 16–18).
Glycolytic activity in T cells is crucial for effector functions in
T cells. This is best described for interferon-γ (INF-γ) production
of CD8+ and CD4+ TEM cells, with multiple mechanisms linking
glycolysis to INF-γ production. For instance, activation-induced
glycolysis is accompanied by increased activity of GAPDH which
promotes chromatin remodeling at the IFNG locus (15). In
resting T cells, on the other hand, GAPDH is not engaged in
glycolysis but is able to inhibit translation of IFNG mRNA by
binding to its untranslated region (19). More broadly, glycolysis
has been linked to pathogenic effector T cell responses in a
variety of disease models, such as allogeneic transplantation
(20), experimental autoimmune encephalitis (21), and systemic
lupus erythematosus (SLE) (22). In these models, inhibiting
glycolysis in T cells ameliorated the disease (21), suggesting that
manipulation of glycolysis represents a promising target for T
cell mediated disease. However, the role of T cell metabolism
seems to be context and disease dependent, because reduced
glycolysis has also been reported to play a pathogenic role in other
disease settings, such as rheumatoid arthritis (23). In contrast to
effector T cells, the importance of glycolysis for regulatory T cells
(TREG) is less well-understood. Depending on the setting within
which TREG cells have been investigated, glycolysis appears to
be necessary or not for their suppressive function (24–26).
Taken together, well-coordinated glycolytic activity is crucial for
proper effector functions in T cells and represents an intriguing
leverage point for therapeutic intervention even though the
precise conditions for this remain to be elucidated.
Tricarboxylic Acid Cycle
Activation of T cells also leads to an increase in their
mitochondrial function. Even in the presence of ongoing
aerobic glycolysis, enough pyruvate is generated to enter the
mitochondria via the mitochondrial pyruvate carrier and fuel
the TCA cycle (14) (Figure 3). This process generates further
molecules for biosynthesis and drives OXPHOS and, thereby,
efficient ATP production. Once in the mitochondria, pyruvate is
converted to acetyl-CoA by pyruvate dehydrogenase, and then
enters the TCA cycle. In the TCA cycle, acetyl-CoA is oxidized
to carbon dioxide and water, which generates GTP and reduces
NAD and FADH, the electron carriers that later fuel OXPHOS
(14). In addition, the TCA cycle generates a number of metabolic
intermediates for anabolic processes such as amino acid and lipid
biosynthesis (27). Other substrates can also be metabolized in the
TCA cycle, such as glutamine via glutaminolysis or fatty acids via
β oxidation (8). Thus, the TCA cycle integrates and mediates the
metabolism of glucose, amino acids, and fatty acids (Figure 4).
In terms of T cell function, the TCA cycle appears to be
critical for proper T cell activation, proliferation, and production
of effector molecules (14). Fatty acid oxidation (FAO) has
been shown to be particularly active and important in TREG
(24, 28), memory T cells, and in skin-resident TRM (29).
Glutaminolysis, the process of breaking down glutamine to α-
ketoglutarate which then enters the TCA cycle, has equally
been observed to be crucial for T cell function (8). After
activation, T cells upregulate their expression of glutamine
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FIGURE 1 | Enzymatic steps of glycolysis. During the 10 enzymatic steps of glycolysis in which glucose is converted to pyruvate, important intermediate molecules for
nucleic acid synthesis, lipid biosynthesis, and amino acid biosynthesis, all of which are important for proliferating T cells, are generated. The sequential enzymatic
reactions of glycolysis occurring in the cytosol generate ATP. The remaining pyruvate can be oxidized in the mitochondria via the tricarboxylic acid cycle and
subsequent oxidative phosphorylation (OXPHOS) to generate ATP. Alternatively, pyruvate can be reduced to lactate and excreted, which mainly happens in
proliferating T cells.
transporters, increase glutamine uptake, and promote expression
of enzymes required for glutaminolysis (13, 16, 30, 31). While
glycolysis-derived pyruvate is a critical substrate for oxidative
phosphorylation, these “alternative” substrates described above
seem to be particularly important to fuel the TCA and thereby
T cell function when there is limited availability of glucose (32).
The importance of the TCA cycle, FAO, or glutaminolysis for T
cell function is exemplified by studies showing that interference
with either FAO or glutamine metabolism has the potential to
alleviate pathology in T cell-mediated diseases (20, 33, 34).
Oxidative Phosphorylation
An important function of the TCA cycle is to generate the
electron carriers NADH and FADH2 by reducing NAD+ and
FADH, respectively. These molecules are then oxidized at the
inner membrane of the mitochondrion, which drives the electron
transport chain (ETC) and finally generates ATP (Figure 4) (14).
The ETC consists of a series of transmembrane proteins located
on the inner mitochondrial membrane (IMM). Complex I and
II of the ETC oxidize NADH and FADH2, respectively, and then
donate the electrons obtained to complex III and later to complex
IV, where they are finally transferred to molecular oxygen which
generates water (10). This process is linked to the transfer of
protons into the intermembrane space of the mitochondria,
which creates an electrical charge between the opposite sides of
the membrane. The last member of the ETC, the ATP synthase,
finally uses this gradient to phosphorylate ADP to ATP, thus
transferring protons back to the mitochondrial matrix. Through
this process, OXPHOS mediates maximal usage of the energy
stored in nutrient molecules such as glucose or fatty acids by
generating 30–36 ATP molecules from one molecule of glucose
and 106 ATP from 1molecule of palmitate (10, 35). Full oxidation
of NADH and FADH2 generated in the TCA, however, requires
the presence of molecular oxygen to serve as acceptor of the
electrons generated by the ETC reactions.
A cell’s mitochondrial mass determines the amount of
OXPHOS a cell can engage in. In response to metabolic
stress, cells can increase their mitochondrial mass in a process
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FIGURE 2 | Activation reprograms T cells to increased usage of aerobic glycolysis. Resting T cells engage OXPHOS and glycolysis to generate energy for
homeostasis and survival. Upon activation, T cells are reprogramed to increase aerobic glycolysis. The relative increase of anaerobic glycolysis after activation provides
less energy, but generates molecules for biosynthesis.
FIGURE 3 | Acetyi-CoA enters the TCA and yields reduced electron carriers (NADH and FADH2) that drive OXPHOS. Once in the mitochondria, pyruvate is converted
to acetyl-GoA by pyruvate dehydrogenase, and then enters the TGA cycle. In the TGA cycle, acetyl-GoA is oxidized to carbon dioxide and water, which generates
GTP and reduces NAD+ and FADH, the electron carriers that later fuel OXPHOS. In addition, the TGA cycle generates a number of metabolic intermediates for
anabolic processes such as amino acid and lipid biosynthesis. Other substrates can also be metabolized in the TGA cycle, such as glutamine via glutaminolysis or
fatty acids via oxidation. Thus, the TGA cycle integrates and mediates the metabolism of glucose, amino acids, and fatty acids.
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FIGURE 4 | The electron transport chain generates ATP via oxidative phosphorylation. The ETC consists of a series of transmembrane proteins located on the inner
mitochondrial membrane (IMM). Complex I and II of the ETC oxidize NADH and FADH2, respectively. Then complex II donates the electrons obtained to complex Ill via
Coenzyme Q and later to complex IV via cytochrome C, where finally they are transferred to molecular oxygen which generates water. This process is linked to the
transfer of protons into the intermembrane space of the mitochondria, which creates an electrochemical proton gradient between the opposite sides of the
membrane. The last member of the ETC, the ATP synthase, finally uses this membrane potential to phosphorylate ADP to ATP, thus letting protons back to the
mitochondrial matrix. Through this process, OXPHOS mediates maximal usage of the energy stored in nutrient molecules such as glucose or fatty acids by generating
30–36 ATP molecules from one molecule of glucose and 106 ATP from one molecule of palmitate. Full oxidation of NADH and FADH2 generated in the TCA, however,
requires the presence of molecular oxygen to serve as acceptor of the electrons generated by the ETC reactions.
referred to as mitochondrial biogenesis (36). In line with their
increased functional repertoire, memory T cells feature increased
mitochondrial mass and function when compared to naive T cells
(14, 37, 38). This is represented by a higher spare respiratory
capacity (SRC) of memory T cells. SRC reflects a cell’s ability to
increase OXPHOS for energy generation in response tometabolic
stress or increased demand as present under hypoxic conditions,
for instance (39). Thus, memory T cells are able to sustain
ATP levels and thereby cellular function even under hypoxia.
It is thought that this represents a metabolic adaptation to the
challenges of immune surveillance in peripheral tissues under
inflammatory conditions where nutrients and oxygen are scarce
(14). Increased respiratory capacity of memory T cells is at least
in part related to increased FAO in the mitochondria (40). T cells
with defects in FAO have impaired memory T cell formation,
whereas enhanced FAO leads to increases in SRC and memory
T-cell generation (37). In circulating memory T cells, the lipids
that fuel FAO seem to derive from triacylglycerols that are
synthesized in the endoplasmic reticulum from glucose-derived
carbon, and not from fatty acid uptake from the environment
(41). Conversely, skin TRM seem to be specialized to take up
fatty acids from the cutaneous environment and use them for
FAO, which is crucial for their function and survival (29). More
broadly, memory T cells critically depend on highly functional
mitochondria for the mounting of recall responses, for rapid
proliferation, calcium signaling, and effector function (14). It
is thus not surprising that impaired mitochondrial function
leads to decreased T-cell functionality, whereas promotion of
mitochondrial function promotes memory T-cell generation and
function in a number of infectious models and in T cell mediated
diseases (14, 22, 42–44).
Amino Acid Metabolism
In addition to glucose, amino acids are crucial nutrients for T
cells as well (8). Adequate supply of amino acids is critical for
T cell growth and function. Amino acids are essential building
blocks for protein synthesis, provide an important backbone for
de novo nucleotide synthesis, and act as metabolic fuel source that
can be fed into multiple pathways (45, 46). Therefore, T cells
upregulate amino acids transporters and increase their uptake
of amino acids immediately after activation (30, 31) which is an
important step in the metabolic reprograming of T cells. Influx
of branched chain amino acids such as leucine lead to activation
of the mTORC1 pathway which is a key event in metabolic
programing of T cells.
In agreement with a central role of amino acid metabolism
in T cell biology, modulation of amino acid levels either
by downregulation of transporters or by limiting amino acid
availability strongly affects T cell activation and function (31,
47). For instance, T helper cells deficient for LAT1 (Slc7a5),
a transporter for phenylalanine, tyrosine, leucine, arginine and
tryptophan, are unable to differentiate into TH1 or TH17 cells,
whereas T reg cell differentiation is still functional (31). This
impaired amino acid metabolism has been linked to reduction
in TORC1 activity and lower expression of Myc, which in turn
impaired the upregulation of the metabolic machinery required
for differentiation in activated T cells. Accordingly, therapeutic
manipulation of amino acid metabolism such as glutamine
metabolism has been shown to inhibit unwanted T cell responses
in animal models of allograft rejection (20). Yet, it appears that
manipulating amino acid metabolism alone is not sufficient to
prevent allograft rejection, since other metabolic pathways had
to be inhibited in parallel to achieve adequate T cell inhibition.
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Interestingly, however, inhibiting amino acid metabolism had
reciprocal effects on T regs as compared to effector T cells,
as these two T cell subsets differentially depend on it. As a
consequence, interference with amino acid metabolism has the
potential to generate antigen-specific regulatory T cells while
impairing pathological effector T cell responses. Furthermore,
amino acids may also directly affect T cell metabolism and
function. Elevating L-arginine levels has been shown to induce
a shift from glycolysis to oxidative phosphorylation in activated
T cells. This was associated with enhanced generation of central
memory-like cells with higher survival and function (48).
Cholesterol and Lipid Metabolism
Lipids and fatty acids make up another group of crucial
T cells substrates. They are important building blocks for
cell membranes, store high amounts of energy, and provide
substrates for cell signaling and post-translational modifications
(8). Not surprisingly, T cells therefore induce cellular lipid
biosynthesis pathways as an integral part of their activation
program (14). These processes are coordinated, at least in
part, by c-Myc and mTOR and transcriptionally regulated by
sterol regulatory element-binding protein (SREBF) transcription
factors (16, 49, 50). SREBFs transcription factors induce gene
expression of enzymes and regulators of fatty acid synthesis and
of the mevalonate pathways, which are involved in synthesis
of cholesterol. Consequently, impairment of SREBF function
or other regulators of cholesterol homeostasis leads to failure
of T cells to efficiently proliferate (50, 51). Furthermore, the
mevalonate pathway may also affect T cell differentiation and
function, either by providing cholesterol precursor or indirectly
via provision of isoprenoids (52).
Fatty acid synthesis also has important effects on T cell
function. Activated T cells can take up fatty acids from the
extracellular space or synthesize them de novo. Interestingly,
different T cell subsets appear to rely differentially on de
novo synthesized fatty acids. In particular, inhibition of fatty
acid synthesis limits TH17 cell differentiation while promoting
generation of TREG cells and these effects translated into
improved disease outcomes in experimental autoimmune
encephalomyelitis (EAE) (8, 28). However, even when T
cells have defective de novo fatty acid synthesis (because of
inhibition/deletion of ACC1 for instance), they can compensate
for the lack of fatty acid synthesis if there are abundant amounts
of fatty acids in the extracellular space, likely through fatty acid
uptake (53). Indeed, skin-resident CD8+ TRM have a highly
effective lipid uptake machinery and are able to metabolize fatty
acids from the cutaneous environment via β-oxidation to support
their long-term survival and function in the skin (29, 54). In
addition, non-TRM effector T cells have been shown to engage
in fatty acid oxidation, although the amount of FAO that occurs
in effector T cells seems to be highly context dependent (8, 32).
Regulation of T Cell Metabolism
The metabolic modules described above have to be finely tuned
in order to support the diverse metabolic needs of T cells
during different states of activation and memory formation. The
metabolic pathways preferably used by T cells based on their
activation and differentiation status are summarized in Table 1.
Failure to adequately meet the demand in energy, biomolecules
and other metabolic mediators leads to T cell dysfunction
and may contribute to disease (14). Although the regulatory
mechanisms that orchestrate these complex metabolic processes
are incompletely understood, two metabolic regulators have been
found to be central regulators of T cell metabolism: mTOR and
AMPK (8).
Mechanistic target of rapamycin (mTOR) has emerged as
a central integrator of environmental signals and cellular
metabolic state to regulate T cell development, activation, and
differentiation. The mTOR protein is a serine/threonine kinase
that can form two different complexes, mTORC1 and mTORC2,
depending on the specific scaffolding proteins it associates with
(10). The different mTOR complexes perform different functions
and are regulated by different stimuli. mTORC1 senses the
availability of factors that are necessary for cell growth and
cell division and links this information with the appropriate
metabolic processes. Signals capable of activating mTORC1 are
amino acids, oxygen, energy availability, and growth factors
(56–59). In situations that are unfavorable for cell growth
or division (low ATP levels, hypoxia, etc.), mTORC1 is not
active and cell growth is inhibited. mTORC2, on the other
hand, is stimulated by growth factors and cytokines while
being irresponsive to nutrient-availability (10, 60). mTORC2
primarily regulates metabolism in support of cell survival and the
cytoskeleton (60).
AMP-activated protein kinase (AMPK) acts to counterbalance
the effects of mTOR. AMPK is an enzyme that functions
as a sensor of cellular energy levels. It is activated by high
AMP/ATP ratios, which result from shortage of nutrients or
other forms of cellular stress. Consequently, activated AMPK
downregulates energy consuming pathways such as biomolecule
synthesis while upregulating those that generate energy, such as
oxidation of glucose and fatty acids (10, 61). Mechanistically,
AMPK has been shown to inhibit activation of mTOR (62).
Given its central role in inhibiting cellular anabolism, it
is not surprising that activation of AMPK suppresses the
differentiation of T cells, as shown in a number of studies
(10, 63–65). It has been proposed that activation of AMPK
might specifically impair differentiation of TH1 and TH17
cells and that this effect is beneficial in animal models of
T cell mediated inflammatory disease (10). However, in most
of these study, it has not been addressed to what extend
these AMPK-mediated effects are primarily T cell intrinsic
or whether they include T cell independent effects of AMPK
modulation. Furthermore, inhibitory effects of AMPK on T cell
differentiation appear to depend on the metabolic environment.
In fact, AMPK has been shown to be dispensable for T cell
differentiation under normal metabolic conditions, since T
cells which lack a functional AMPK are still able to acquire
effector functions but fail to differentiate under suboptimal
environmental conditions (32, 66). Taken together, AMPKmight
thus primarily function to mediate T cell adaptation to situations
of low nutrient availability as encountered in hypoxic and
glucose-deprived microenvironments of peripheral tissues under
inflammatory conditions.
Frontiers in Immunology | www.frontiersin.org 6 September 2019 | Volume 10 | Article 2285
von Meyenn et al. Targeting T-Cell Metabolism in Skin
TABLE 1 | Metabolic pathways of T cell subsets according to differentiation and activation status.
T cell subset Anaerobic glycolysis Aerobic glycolysis Fatty acid oxidation Fatty acid synthesis OXPHOS
Naive T cell + ++ ++ – ++
Early activated T cell ++ +++ – +++ +
Late activated T cell ++ + +++ – ++
Memory T cell ++ + ++ ++ ++
TRM N.D. + +++ N.D. +++
Adapted from Veldhoen et al. (55).
T Cell Metabolism–Conclusions
In recent years, research on T cell metabolism has attracted
great attention and generated substantial insights into the
intricate links between T cell function and T cell metabolism.
Although many aspects of the complex mechanisms that link
these central aspects of T cell biology remain to be elucidated,
it is unquestioned that the therapeutic manipulation of T cell
metabolism holds great potential in immune mediated disease.
It seems possible that 1 day, overactive T cells in inflammatory
disease can be curbed and exhausted T cells in cancer can be
activated through manipulation of their metabolism. Before such
therapies can be developed, however, many obstacles remain to
be overcome, one of which is the fact that metabolism is a central
function of all cells. Developing means to specifically target T
cells will thus be a key step on the way to metabolism based T
cell manipulation in health and disease.
T CELL METABOLISM IN INFLAMMATORY
SKIN DISEASE
Effects of the Metabolic Microenvironment
on T Cell Function
As outlined above, a T cell’s ability to survive, proliferate, and
exert effector functions is highly dependent on its metabolic state.
In turn, a T cell’s metabolic state is highly dependent on the
microenvironment, since it is the source from which T cells take
up the nutrients they require for their proper functioning (32,
67). Studies in the field of cancer immunology have established
that limited nutrient availability in the microenvironment can
profoundly affect T cell effector functions (68). Conversely, high
concentrations of tumor derived metabolites such as lactate
can hinder activation of tumor-infiltrating T cells (69, 70).
Although there is a lack of studies actually quantifying the
metabolic microenvironment in inflammatory skin disease, it is
likely that these interactions between T cells and the cutaneous
environment of inflamed skin are equally important for T
cell function.
Secondary lymphoid tissues such as the lymph nodes provide
a nutrient-rich environment optimal for survival, activation, and
growth of T cells (71, 72). However, once T cells migrate into
peripheral tissues like the skin, they are forced to metabolically
adapt to the local conditions, which may differ substantially
in terms of nutrient availability (55). It is assumed that the
microenvironment of the skin is restricted in many nutrients,
particularly glucose, but is rich in lipids.While this is a reasonable
assumption to make, based on the anatomy and biochemical
make-up of the skin, it is important to note that cutaneous
interstitial glucose, amino acid, or fatty acid levels have never
been quantified comprehensively, neither under homeostatic
nor under inflammatory conditions (73, 74). Future studies are
needed to address this in more detail. At any rate, it is likely that
T cells encounter a metabolic environment in the skin that is very
different from that in blood or in lymphoid tissues and therefore
have to adapt metabolically.
An outstanding example of such a metabolic adaptation is
the specialization of skin TRM for uptake and β-oxidation of
exogenous free fatty acids to support their long-term survival
and function (29). The skin is a primary interface between the
body and the environment and thus represents a site of first
line defense against microbial pathogens, physical damage, and
chemical harm (54). This “immunological hotbed” is populated
by large numbers of sessile, non-migratory skin-resident T cells
(skin TRM) which function to provide rapid on-site immune
protection against known pathogens (4). Besides the skin, TRM
cells are also found in all other major epithelial barrier tissues,
such as the lung and the gastro-intestinal tract (55, 75, 76).
In a landmark study by Pan et al., the transcriptional program
of CD8+ TRM in skin was determined before and after their
generation by vaccination with vaccinia virus (skin scarification).
Strikingly, CD8+ TRM upregulated a transcriptional program
that was strongly enriched for genes associated with uptake and
metabolism of exogenous free fatty acids as they differentiated
into bona fide TRM 90 days post-vaccination. Amongst the
top upregulated genes were fatty acid binding proteins 4 and
5 (Fabp4/5), Cd36, and lipoprotein lipase (Lpl), all of which
are genes involved in lipid uptake and fatty acid metabolism.
The lipoprotein lipase Lpl cleaves triglycerides into free fatty
acids and diacylglycerol. Cd36 is a lipid scavenger receptor
able to bind and internalize free fatty acids. Fatty acid binding
proteins are intracellular chaperones able to shuttle FFAs
from the cytoplasm to the mitochondria for β-oxidation. This
transcriptional signature of TRM was further confirmed to have
important functional relevance. TRM were shown to have a
higher capacity to take up free fatty acids from the environment
and a higher capacity to perform mitochondrial fatty acid β-
oxidation when compared to TCM or TEM. This was crucial
for the proper functioning of TRM, as inhibition of these
metabolic pathways resulted in decreased generation, persistence
and function of TRM in the skin. For instance, pre-treatment of
CD8+ T cells with etomoxir, an irreversible inhibitor of carnitine
palmitoyltransferase 1 (CPT1a) which catalyzes the rate limiting
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step for mitochondrial fatty acid β-oxidation, strongly impaired
the generation and maintenance of skin TRM.
In the study by Pan et al., the expression of Fabp4/5 in
TRM was shown to be regulated by peroxisome proliferator-
activated receptor gamma (PPARγ) (29). Pharmacological
inhibition or genetic deletion of PPARγ in T cells resulted in
decreased generation and function of TRM post-skin scarification.
Interestingly, PPARγ is also increasingly implicated in the
regulation of “pathogenic” TH2 cells in both humans and mice
(77). Pathogenic TH2 cells are a subset of TH2 cells that contain
all allergen-specific TH cells in humans (78), provide superior
protection in models of parasite infection (79) and mediate tissue
pathology in models of allergic inflammation (80). In addition
to their dependence on PPARγ, pathogenic TH2 cells have been
shown to express high levels of IL-9 (78). Intriguingly, IL-9 is
a cytokine that is preferentially expressed by skin-homing and
skin-resident TH cells (81, 82). Furthermore, this population
of IL-9+ TH cells was recently found to express high levels
of PPARγ which in turn acts as positive regulator of IL-9
expression in these cells (83). These PPARγ+ IL-9+ TH cells were
further found to infiltrate lesions of allergic contact dermatitis, a
prototypical TRM mediated disease (84). Taken together, PPARγ
emerges as an important regulator of both tissue resident and
pathogenic T cells. The underlying reason for this link might
be that PPARγ confers a metabolic advantage to T cells that
enter the cutaneous microenvironment by mediating metabolic
adaptation. Given that PPARγ is a well-established drug target,
it appears possible that both CD8+ and CD4+ TRM will 1
day be targeted via this metabolically relevant transcription
factor (85).
Tissue inflammation is intricately linked to hypoxia (86).
Hypoxia is a strong inducer of metabolic reprogramming
in T cells and activation of the hypoxia response has been
shown to cause T cell dysfunction and contribute to disease
(87). In particular, hypoxia drives glycolysis to maintain ATP
production, thus compensating for reduced OXPHOS activity
under conditions of limited oxygen pressure (87). This process
is critically regulated by the transcription factor HIF-1α, whose
activation induces the expression of glycolytic enzymes such
as hexokinase and phosphofructokinase, to ramp up glycolysis
(see also section Regulation of T Cell Metabolism) (5, 88).
Overactive glycolysis, in turn, has been identified as a hallmark
of pathogenic T cells in inflammatory and autoimmune disease
(20–22, 67). Activation of HIF-1α may also directly affect the
balance between pathogenic TH17 cells and regulatory TREG
cells. HIF-1α directly binds FOXP3 and promotes its proteasomal
degradation, thereby impeding TREG differentiation. Conversely,
HIF-1α directly activates RORγt and thus promotes IL-17
expression and TH17 differentiation (89). Addressing the hypoxia
response in inflammatory skin disease might thus represent a
promising new leverage point for therapy. In fact, certain drugs
currently used to treat inflammatory skin disease may act via
the modulation of the hypoxia response in T cells. For instance,
dimethyl fumarate (DMF), used in the treatment of psoriasis, is
thought to impair the HIF-1α-induced response by promoting its
degradation (90). Inhibition of glycolysis by 2-Desoxy-D-glucose
(2-DG) or other inhibitors of glycolysis might further help to
restore the balance between TH17 and TREG cells in skin diseases
such as psoriasis.
Metabolic Competition Between Different
Cell Types in the Skin
Just as T cells themselves, other cells of the skin organ
also critically depend on nutrients for their functioning.
Innate immune cells (91, 92), keratinocytes (93), endothelial
cells (94, 95), stromal cells (96), amongst others, thus all
engage in a competition for metabolites with T cells and
thereby establish a bidirectional metabolic relationship (55).
This competition will be especially active under inflammatory
conditions, where cells proliferate and undergo metabolic
reprograming. For instance, keratinocytes critically depend on
increased glucose uptake via the glucose transporter Glut1 for
injury- or inflammation-associated keratinocyte proliferation
(93). Consequently, inactivation of Glut1 in keratinocytes
decreased psoriasis-like inflammation in mouse models and in
human psoriatic skin organoids. Interestingly, when Glut1 was
uniquely deleted in keratinocytes by means of conditional knock-
out, the immune response in the skin in animal models of
psoriasis was not abrogated. Conversely, topical inhibition of
glucose transport using a chemical GLUT1 inhibitor inhibited
not only keratinocyte proliferation but also prevented infiltration
and activation of immune cells. This discrepancy between genetic
deletion of GLUT1 in keratinocytes and cell type-independent
pharmacological inhibition of Glut1 suggests that this glucose
transporter plays a crucial role in the facilitation of the immune
response in psoriasis. Thus, inhibiting GLUT1 on T cells (and
other immune cells) may be a highly effective therapeutic
approach in psoriasis, given that GLUT1 is critical for T cell
effector function (6). In fact, there is evidence that regulating
glycolysis in T cells might be used to modulate autoimmunity.
Overexpression of Glut1 in murine T cells boosts activation-
induced production of IL-2 and IFN-γ. In mice carrying such
T cells, accumulation of highly activated memory T cells was
observed in conjunction with high levels of circulating IgG
and deposit of IgG in the kidney. This suggests that Glut1
overexpression in T cells alone may contribute to autoimmunity
(12). Conversely, knock-out of Glut1 in TH cells is sufficient to
reduce their glycolytic activity, to impair generation of effector T
cells, and to reduce inflammatory disease in vivo (6, 97).
Targeting T Cell Metabolism in
Inflammatory Skin Disease
Despite considerable recent advances in the field, many insights
into the metabolic pathways critical for T cell function derive
from in vitro T cell assays. However, these are reductionist
representations of the complex metabolic situations in the
microenvironment in vivo (68). Therefore, it remains to be
discovered in more detail how exactly T cell immunometabolism
is affected in inflammatory skin disease. Nevertheless, by
observing how modulating the major metabolic modules affects
experimental pathology, some interesting perspectives can be
identified and are discussed below.
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The mechanisms by which modulation of glycolysis in T
cells affects inflammatory pathology has been investigated in
some detail. Effector TH cells and CD8+ T cells show increased
glycolytic activity as compared to naive T cells (16, 67), but not
all TH cell lineages have equal glucose metabolism signatures.
For instance, TH cells show reduced differentiation into TH1
and TH17 cells in vitro when glycolysis is inhibited, while
inducible TREG differentiation is enhanced in low glucose
conditions (24, 98). This affects TEFF/TREG balance which in
turn has been related to reduced pathology in experimental
autoimmune encephalomyelitis (98). To what extent modulation
of glycolysis can be leveraged to specifically boost or inhibit
distinct TH cell subsets is an active area of current research
(67). In the context of skin inflammation, it will be crucial to
consider the complex interplay between glucose availability in the
tissue, glucose consumption by different skin-resident immune,
stromal, and epithelial cell populations, and their differential
glucose dependence for inflammatory reactions. A summary
categorizing key metabolic properties of different T cell subsets
in the context of inflammatory skin disease is shown in Table 2.
As outlined in more detail above, amino acids are another
important substrate for T cell function. Availability of amino
acids is likely to change significantly in inflamed skin, which in
turn will shape T cell function. T cells require amino acids for
protein and nucleic acid synthesis (67) and restriction of amino
acids can differentially affect T cell activation via regulation of
mTORC1 activation and other pathways (100). In the context of
psoriasis, a TH17-driven skin disease, activating the amino acid
starvation response through halofuginone or restricting amino
acid flux into T cells might be of therapeutic interest, since
it decreases TH17 differentiation, while leaving TH1 nor TH2
cell polarization unaffected (101, 102). Furthermore, glutamine
availability for T cells also impacts differentiation of TH cells. If
glutamine is restricted, TH cells polarized under TH1 conditions
are skewed into a TREG phenotype, whilst again leaving TH2
polarization unaffected. Similar findings were made when uptake
of glutamine into T cells is inhibited by genetic deletion of the
glutamine transporter Slc1a5 (47). Taken together, interference
with amino acid metabolism of T cells might be used to improve
inflammatory skin disease, particularly psoriasis, as it has been
shown to enable therapeutic intervention in multiple TH17-
driven disease models (47, 67, 101). A number of molecules to
inhibit cellular glutamine metabolism are in fact available, some
of which are currently being tested clinically in oncological trials
(see Table 3) (106, 108).
Modulation of T cell lipid metabolism might also be leveraged
to improve inflammatory skin disease. Typically, skin diseases
such as psoriasis and atopic dermatitis are characterized by
exacerbated activation and proliferation of T cells in the skin
(109). Proliferating cells depend on de novo fatty acid and
cholesterol synthesis as building blocks for the plasmamembrane
and membranes of organelles. In this regard, there are intriguing
differences in the dependence on de novo lipogenesis between
TH17 cells and TREG cells. In particular, if fatty acid synthesis
is inhibited by an inhibitor of acetyl-CoA Carboxylase 1
(ACC1, also known as ACACA), TH17 cell differentiation and
proliferation is reduced while TREG cells are induced (28). ACC1
is an enzyme which catalyzes the carboxylation of acetyl-CoA
to malonyl-CoA, the rate-limiting step in fatty acid synthesis. T
cells that lack ACC1 show reduced de novo synthesis of palmitate
and defective TH17 cell differentiation. This phenotype can be
rescued by exogenous palmitate. Mice harboring ACC1-deficient
T cells are less susceptible to EAE which underscores the crucial
role of lipid metabolism in pathogenic TH17 cell responses and
points to a novel therapeutic opportunity in psoriasis (Table 3).
Finally, the particular dependence of skin TRM on β-
oxidation of exogenous free fatty acids from the cutaneous
environment to fuel their metabolism might represent a weak
spot that could be exploited therapeutically (29, 54). In fact, it is
increasingly appreciated that chronic and/or aberrant activation
of pathogenic TRM represents a key pathogenetic step in the
onset and maintenance of many inflammatory skin diseases (3).
Psoriasis (110), atopic dermatitis (111), vitiligo (112), cutaneous
adverse drug eruption (113), and many other skin diseases
have all been shown to be—at least in part—mediated by
TRM. This provides an elegant explanation for the chronicity
of T cell mediated skin diseases and their general tendency to
relapse once immunosuppressive treatment is withdrawn. Thus,
therapies that not only suppress but actually dislodge pathogenic
TRM from their tissue niches in the skin may tackle these
diseases at their very root and induce persistent remission. In
mouse models, in vivo inhibition of mitochondrial β-oxidation
with trimetazidine or etomoxir decreased the survival and
maintenance of cutaneous TRM and hence show the fundamental
feasibility of such therapeutic strategies (29). To what extend such
approaches are transferrable to humans will have to be addressed
by future studies.
Crosstalk Between Systemic Metabolism
and Skin Inflammation
Both severe psoriasis and severe atopic dermatitis are associated
with diseases of the metabolic syndrome (114, 115). Although
the reasons for this are incompletely understood, it is known
that inflammation can modulate local and systemic metabolism
and–vice versa local–that systemic metabolism can profoundly
influence immune function (116, 117). Therefore, metabolism
and immune function might interact in specific ways to
drive aberrant inflammation in inflammatory skin disease. For
instance, statins have been proposed to ameliorate psoriasis
and their beneficial effects have been attributed to their effects
on lipid metabolism in skin, as well as their proclaimed
anti-inflammatory and immunomodulatory properties (118). In
mice, it has indeed been shown that inhibition of HMG-CoA
reductase has an inhibitory effect on TH17 cell differentiation
(119). Future studies will have to address whether inhibition
of HMG-CoA reductase with statins is truly beneficial in
inflammatory skin diseases such as psoriasis and whether this
potentially beneficial effect is mediated by interference with
TH17 cell function. In fact, statins may also influence T
cell function and inflammation via their inhibitory effect on
mitochondrial function. Statins have been shown to inhibit
mitochondrial complex III of the respiratory chain (120),
leading to reduced generation of mitochondrial reactive oxygen
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TABLE 2 | T cell subsets in inflammatory skin disease (ISD) and their engagement of key metabolic pathways.
T cell subset Representative ISD Glycolysis Amino acid metabolism Fatty acid synthesis Mitochondrial biogenesis
CD4+ TH1 ACD/Lichen planus ++ +++ + ++
TH2 Atopic Dermatitis +++ N.D. N.D. +
TH17 Psoriasis ++ ++ +++ +++
TFH Lupus/AIBD + N.D. N.D. ++
CD8+ CTLs Severe drug reactions (SJS/TEN) ++ +++ ++ +++
ACD, allergic contact dermatitis; AIBD, autoimmune bullous disease; CTL, cytotoxic T lymphocyte; SJS, Stevens-Johnson-Syndrome; TEN, Toxic epidermal necrolysis. Adapted from
Bantug et al. (67) and Eyerich et al. (99).
TABLE 3 | Pharmacological modulators of T cell metabolism and their putative therapeutic application in inflammatory skin disease.
Pathway Drug Effect Target Cellular effects Effects on T cell
function/phenotype
Putative effect on ISD References
Glucose
metabolism
WZB117 INH GLUT Inhibits glucose uptake Reduced
TH1/TH17 polarization
Enhanced
iTreg differentiation
Beneficial in ISD with
pathologic TH17/Treg
balance (e.g., PSO)
Macintyre et al. (6),
Zhang et al. (93)
2-DG INH Hexokinase (HK) Inhibits rate limiting
step of glycolysis
Shi et al. (98)
SF2312 INH Enolase (ENO) Inhibits rate limiting
step of glycolysis
Gemta et al. (103)
Pyruvate
metabolism
DCA INH Pyruvate
dehydrogenase
kinase 1 (PDHK1)
Inhibits conversion of
pyruvate to acetyl-CoA
and glycolysis
Lee et al. (20)
Amino acid
metabolism
CB-839 INH Glutaminase (GLS) Inhibits glutaminolysis
and
glutamine-dependent
metabolism
Skewing into Treg
phenotype
Beneficial in ISD with
pathologic TEFF/Treg
balance (e.g., PSO, AD)
Johnson et al. (104)
DON ANT Glutamine antagonist Decreased glutaminase
activity, IFN-γ
production, and
proliferation
prevention of transplant
rejection (MHC
mismatch)
Beneficial in
Graft-vs.-host-disease
Lee et al. (20)
RZ-2994 INH Serine hydroxymethyl
transferase (SHMT)
Inhibits serine
biosynthesis
Reduced
macromolecular
biosynthesis and
redox balance
Reduced proliferation
Impaired
(auto-)antigen-specific
T cell responses
Benficial in
(auto)antigen-driven T
cell-mediated ISD (e.g.,
ACD, AIBD)
Ma et al. (105),
Luengo et al. (106)
HF INH Glutamyl-prolyl-tRNA
synthetase (EPRS)
Activates amino acid
starvation response
Impaired TH17
polarization
Beneficial in ISD with
pathologic TH17
responses (e.g., PSO)
Sundrud et al. (101),
Keller et al. (102)
Fatty acid
oxidation
Etomoxir INH Carnitine
palmitoyltransferase
1 (CPT1a)
Inhibits mitochondrial
fatty acid β-oxidation
Decreased generation,
persistence, and
function of TRM
Beneficial in
TRM-mediated ISDs
(e.g., PSO, ACD)
Pan et al. (29, 54)
GW9662 INH PPAR-γ Inhibits upregulation of
FABP4/5 and FAO
Metbolic
regulators
Rapamycin INH mTORC1
(>mTORC2)
Inhibits translational
activity, cell cycle
progression, and cell
proliferation
Reduced TH1/TH17
polarization
Enhanced
iTreg differentiation
Beneficial in ISD with
pathologic TH17/Treg
balance (e.g., PSO)
Pallet et al. (107),
Pollizzi and Powell
(59)
ACD, allergic contact dermatitis; AD, atopic dermatitis; AIBD, autoimmune-bullous disease; ANTAG, antagonist; DCA, Dichloroacetate; DON, 6-Diazo-5-oxo-L-norleucine; FABP, fatty
acid binding protein; FAO, fatty acid oxidation; GLUT, glucose transporter; HF, halofuginone; INH, inhibitor; ISD, inflammatory skin disease, PSO, psoriasis.
species (mROS). Reduced levels of mROS, in turn, reduce
activation of nuclear factor of activated T cells (NFAT) and
IL-2 production in T cells (121), thus providing an additional
putative mechanism by which statins may alleviate inflammatory
skin disease.
In addition, dietary fatty acids from nutrition may also affect
systemic immune responses and autoimmunity. In mice, dietary
long-chain fatty acids enhance differentiation and proliferation
of TH1 and TH17 cells whereas dietary short-chain FAs expanded
gut TREG cells. These nutrition-dependent effects translated
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into exacerbated EAE via the expansion of pathogenic TH1
and/or TH17 cell populations (122). Furthermore, a diet high
in saturated fatty acids is sufficient to exacerbate psoriatic skin
inflammation independent of obesity (123) and this effect seems
to be linked to an augmented TH17 response in the skin (124).
Given that weight loss through diet adaptation can improve pre-
existing psoriasis and prevent the onset of psoriasis in obese
individuals it can be speculated that the beneficial effects thereof
are at least in partmediated through an altered cross-talk between
systemic metabolism and local T cell function (125). In addition
to fatty acid metabolism, systemic amino acid levels may also
affect T cell function in the skin. This has best been studied for
the amino acid arginine which is an important modulator of T
cell function (48, 126, 127). In animal models, increased dietary
arginine enhanced T cell maturation and led to increased contact
allergy reactions (128). It is thus possible that systemic and local
cutaneous arginine levels may shape the immune response in
inflammatory skin diseases.
At any rate, our understanding of the diverse processes
that integrate with lymphocyte signaling, gene regulation,
and function to shape T cell metabolism is still nascent. A
better understanding of the metabolic regulation in T cells
and the influence of nutrients in the microenvironment
on T cell function will lead to novel insights into
T cell function in the context of skin disease. This
knowledge may open up new therapeutic approaches in
the future.
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